Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.
EN | CN

You are here:Home-Chemical Inhibitors & Agonists-Nuclear Receptor/Transcription Factor-Androgen Receptor (AR)-Rezvilutamide
Rezvilutamide

Chemical Structure : Rezvilutamide

CAS No.: 1572045-62-5

Rezvilutamide (SHR3680)

Catalog No.: PC-38370Not For Human Use, Lab Use Only.

Rezvilutamide (SHR3680) is a novel and pure androgen-receptor (AR) antagonist that shows potent antitumor activity against castration-resistant prostate cancer (CRPC) but with much less brain distribution than enzalutamide.

Packing Price Stock Quantity
5 mg $198 In stock
10 mg $298 In stock
25 mg $498 In stock
50 mg Get quote
100 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

Rezvilutamide (SHR3680) is a novel and pure androgen-receptor (AR) antagonist that shows potent antitumor activity against castration-resistant prostate cancer (CRPC) but with much less brain distribution than enzalutamide.

Physicochemical Properties

M.Wt 479.474
Formula C22H20F3N3O4S
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

(S)-4-(3-(4-(2,3-dihydroxypropoxy)phenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile

References

1. Xiaojian Qin, et al. BMC Med. 2022 Mar 4;20(1):84.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: